Cardinal Health posted $25.2 billion in revenue for its 2013 second quarter, down 7%. The company's non-GAAP diluted earnings per share was up 15% to $0.93.
Ranbaxy Labs has launched a new treatment for acne under a licensing agreement with a Canadian drug maker.